Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
// Rochelle L. Tiedemann 1 , Ryan A. Hlady 2 , Paul D. Hanavan 3 , Douglas F. Lake 3 , Raoul Tibes 4,5 , Jeong-Heon Lee 5,6 , Jeong-Hyeon Choi 7 , Thai H. Ho 4,5 and Keith D. Robertson 2,5 1 Center for Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA 2 Department of Molecular Pharmacology and Experimental Therapeutics and Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Rochester, MN, USA 3 School of Life Sciences, Mayo Clinic Collaborative Research Building, Arizona State University, Scottsdale, AZ, USA 4 Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, USA 5 Epigenomics Translational Program, Center for Individualized Medicine, Rochester, MN, USA 6 Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA 7 Department of Biostatistics, Georgia Regents University, Augusta, GA, USA Correspondence to: Thai H. Ho, email: // Keith D. Robertson, email: // Keywords : DNA methylation, epigenetics, SETD2, histone methylation, renal cell cancer Received : September 08, 2015 Accepted : November 16, 2015 Published : December 05, 2015 Abstract Clear cell renal cell carcinomas (ccRCCs) harbor frequent mutations in epigenetic modifiers including SETD2, the H3K36me3 writer. We profiled DNA methylation (5mC) across the genome in cell line-based models of SETD2 inactivation and SETD2 mutant primary tumors because 5mC has been linked to H3K36me3 and is therapeutically targetable. SETD2 depleted cell line models (long-term and acute) exhibited a DNA hypermethylation phenotype coinciding with ectopic gains in H3K36me3 centered across intergenic regions adjacent to low expressing genes, which became upregulated upon dysregulation of the epigenome. Poised enhancers of developmental genes were prominent hypermethylation targets. SETD2 mutant primary ccRCCs, papillary renal cell carcinomas, and lung adenocarcinomas all demonstrated a DNA hypermethylation phenotype that segregated tumors by SETD2 genotype and advanced grade. These findings collectively demonstrate that SETD2 mutations drive tumorigenesis by coordinated disruption of the epigenome and transcriptome,and they have important implications for future therapeutic strategies targeting chromatin regulator mutant tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine
Ito, S., Shen, L., Dai, Q., Wu, S. C., Collins, L. B., Swenberg, J. A., He, C., & Zhang, Y. (2011) · Science · doi:10.1126/science.1210597 · Cited by 3,451
Widespread transcription at neuronal activity-regulated enhancers
Kim, T.-K., Hemberg, M., Gray, J. M., Costa, A. M., Bear, D. M., Wu, J., Harmin, D. A., Laptewicz, M., Barbara-Haley, K., Kuersten, S., et al. (2010) · Nature · doi:10.1038/nature09033 · Cited by 2,450
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · cited 1×
“com/oncotarget the tumors more sensitive to DNA hypomethylating agents [45, 46].”
Charting a dynamic DNA methylation landscape of the human genome
Ziller, M. J., Gu, H., Müller, F., Donaghey, J., Tsai, L. T.-Y., Kohlbacher, O., De Jager, P. L., Rosen, E. D., Bennett, D. A., Bernstein, B. E., et al. (2013) · Nature · doi:10.1038/nature12433 · Cited by 1,357 · cited 1×
“Active enhancers are typically devoid of 5mC as these regions are hotspots for transcription factor binding [34].”
BackgroundGene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199 · cited 4×
“Thus the presence of 5mC at or flanking certain enhancers may be indicative of enhancer activation much in the same way gene body 5mC is linked positively to gene activity [21].”
BackgroundMethodInfluentialSystematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173 · cited 1×
“RAS, BRAF, TP53, RB) are largely absent [2-5], and ccRCC is tightly linked to a distinct transcriptional signature due to inactivation of the VHL gene, which is mediated in part through deregulation of the epigenome [6].”
BackgroundEpigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143 · cited 1×
“The Fisher Exact test with a two-tailed p-value calculation was used for testing the significance of data set comparisons as described previously for similar data sets [51].”
MethodGenomic profiling of DNA methyltransferases reveals a role for DNMT3B in genic methylation
Baubec, T., Colombo, D. F., Wirbelauer, C., Schmidt, J., Burger, L., Krebs, A. R., Akalin, A., & Schübeler, D. (2015) · Nature · doi:10.1038/nature14176 · Cited by 705 · cited 3×
“Since H3K36me3 and 5mC overlap significantly in their genome-wide distribution [21, 26, 30, 31] we next assayed DNA methylation patterns in the 786-O isogenic clones using the Illumina HumanMethylation450 BeadChip (450K array).”
BackgroundMethodEpigenetic signatures distinguish multiple classes of enhancers with distinct cellular functions
Zentner, G. E., Tesar, P. J., & Scacheri, P. C. (2011) · Genome Research · doi:10.1101/gr.122382.111 · Cited by 564
Cited by
The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.075 · Cited by 770
Self-citationThe Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma
Ricketts, C. J., De Cubas, A. A., Fan, H., Smith, C. C., Lang, M., Reznik, E., Bowlby, R., Gibb, E. A., Akbani, R., Beroukhim, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.032 · Cited by 734
Self-citationThe Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 621
The interplay between DNA and histone methylation: molecular mechanisms and disease implications
Li, Y., Chen, X., & Lu, C. (2021) · The EMBO Reports · doi:10.15252/embr.202051803 · Cited by 223
Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.07.013 · Cited by 105
Metadata
- Authors
- Tiedemann, R. L., Hlady, R. A., Hanavan, P. D., Lake, D. F., Tibes, R., Lee, J.-H., Choi, J.-H., Ho, T. H., & Robertson, K. D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-12-05
- Volume
- 7
- Issue
- 2
- Pages
- 1927-1946
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2280868186
- Cited by
- 62
- References
- 15
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. https://app.cochat.ai/papers/10.18632/oncotarget.6481
- The paper
- Tiedemann, R. L., Hlady, R. A., Hanavan, P. D., Lake, D. F., Tibes, R., Lee, J.-H., Choi, J.-H., Ho, T. H., & Robertson, K. D. (2016). Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma. Oncotarget. https://doi.org/10.18632/oncotarget.6481
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.